These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 20424448)

  • 1. Animal models related to congenital heart disease and clinical research in pulmonary hypertension.
    Loukanov T; Geiger R; Agrawal R
    Cardiology; 2010; 116(1):18-25. PubMed ID: 20424448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
    Sharkovska Y; Kalk P; Lawrenz B; Godes M; Hoffmann LS; Wellkisch K; Geschka S; Relle K; Hocher B; Stasch JP
    J Hypertens; 2010 Aug; 28(8):1666-75. PubMed ID: 20613628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riociguat for pulmonary hypertension.
    Ghofrani HA; Voswinckel R; Gall H; Schermuly R; Weissmann N; Seeger W; Grimminger F
    Future Cardiol; 2010 Mar; 6(2):155-66. PubMed ID: 20230258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
    Ghofrani HA; Hoeper MM; Halank M; Meyer FJ; Staehler G; Behr J; Ewert R; Weimann G; Grimminger F
    Eur Respir J; 2010 Oct; 36(4):792-9. PubMed ID: 20530034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Lian TY; Jiang X; Jing ZC
    Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Mielniczuk LM; Swiston JR; Mehta S
    Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The oxygen kinetic effect of inhaled iloprost in pulmonary artery hypertension and chronic thromboembolic pulmonary hypertension].
    Cui N; Yang YH; Xie WM; Ma ZH; Luo L; Wang C
    Zhonghua Jie He He Hu Xi Za Zhi; 2009 Jul; 32(7):522-6. PubMed ID: 19954007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
    Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riociguat: a novel new drug for treatment of pulmonary hypertension.
    Makowski CT; Rissmiller RW; Bullington WM
    Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Belik J
    Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dana Point: what is new in the treatment of pulmonary hypertension?].
    Hoeper MM; Ghofrani HA; Grimminger F; Rosenkranz S
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S191-5. PubMed ID: 18814094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy.
    Ghofrani HA; Grimminger F
    Eur Respir Rev; 2009 Mar; 18(111):35-41. PubMed ID: 20956121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design.
    Ghio S; Bonderman D; Felix SB; Ghofrani HA; Michelakis ED; Mitrovic V; Oudiz RJ; Frey R; Roessig L; Semigran MJ
    Eur J Heart Fail; 2012 Aug; 14(8):946-53. PubMed ID: 22719060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congenital heart disease.
    Gorenflo M; Gu H; Xu Z
    Cardiology; 2010; 116(1):10-7. PubMed ID: 20424447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.
    DeSouza SA; Preston IR
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):467-76. PubMed ID: 25797801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riociguat for the treatment of pulmonary hypertension.
    Schermuly RT; Janssen W; Weissmann N; Stasch JP; Grimminger F; Ghofrani HA
    Expert Opin Investig Drugs; 2011 Apr; 20(4):567-76. PubMed ID: 21391889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.
    Evgenov OV; Ichinose F; Evgenov NV; Gnoth MJ; Falkowski GE; Chang Y; Bloch KD; Zapol WM
    Circulation; 2004 Oct; 110(15):2253-9. PubMed ID: 15466650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM
    Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
    Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.